A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC)
A Phase 2, Fast Real-Time Assessment of Combination Therapies in Immuno-Oncology Study in Participants with Advanced Gastric Cancer (FRACTION-Gastric)
Investigator
Trial Phase
Phase II
Study Number
Local Study ID
20162429
Trial Contact Phone
800-804-8824 / 206-606-1024
Summary
The purpose of this study is to determine whether Nivolumab in combination with other therapies is more effective than Nivolumab in combination with Ipilimumab in treating patients/subjects with advanced gastric cancer.
Trial Eligibility
*For Eligibility information, look up the trial at NIH by clicking on the Study Number above.*
Other eligibility criteria may apply.
Trial Exclusions
Other exclusion criteria may apply.
Trial Keywords
Esophageal Cancer; Gastric Cancer; Gastrointestinal Cancer; Solid Tumors; Stomach Cancer; Immunotherapy; Esophageal Diseases; Digestive System Diseases